Medici List

TSOL is a Delaware statutory trust that issues shares trading on the Cboe BZX under the symbol TSOL, acting as a passive, ETF‑like vehicle to track the price of Solana (SOL) using the CME CF Solana‑Dollar Reference Rate and to reflect staking rewards net of fees.

Allurion develops and sells a metabolically focused weight‑loss platform centered on the Allurion Smart Capsule — a swallowable, procedureless intragastric balloon — paired with a digital care ecosystem (Allurion Virtual Care Suite, patient app, connected scale, and provider Insights dashboard) delivered via a B2B2C model across 50+ countries.

Specialty pharmaceutical company focused on infectious diseases, developing and commercializing therapies including Arakoda (tafenoquine) for malaria prevention and advancing programs in babesiosis, celgosivir/castanospermine extracts, and veterinary applications.

Clinical-stage precision-medicine pharmaceutical company developing stenoparib (a dual PARP1/2 and tankyrase inhibitor) and the DRP® companion diagnostic platform to identify patients most likely to benefit from targeted cancer therapies.

AEON Biopharma, Inc. is a SPAC-derived biopharmaceutical company developing ABP-450, a 900 kDa botulinum toxin biosimilar to Botox for therapeutic indications, relying on Daewoong for manufacturing and IP and with limited cash runway.

APHP is a publicly traded independent film co‑financier and co‑producer that develops, finances, and packages feature films and limited series, emphasizing structured film finance, IP acquisition, and selective strategic partnerships.

Avenue Therapeutics is a Fortress-controlled specialty pharmaceutical company developing ATX-04 (clenbuterol) for lysosomal storage diseases (initially Pompe disease) and IV tramadol for postoperative pain, with no approved products and minimal internal resources.

Company Name (placeholder) reported a net loss of $17,298,000 in 2025 (compared with a net loss of $19,791,000 in 2024), total assets of $47,892,000 and cash of $5,200,000; the provided statements do not report revenue, customer count, or employee count.

Annexon is a clinical-stage biopharmaceutical company developing targeted immunotherapies that selectively inhibit the classical complement cascade (starting at C1q) to treat autoimmune, neurodegenerative, and ophthalmic diseases.

AIxCrypto Holdings, Inc. is a Nasdaq-listed technology infrastructure company building regulatory-aware real-world asset tokenization and Embodied AI deployment platforms to connect traditional capital markets with on-chain and AI-enabled commercial systems.

Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted alpha-emitter radiopharmaceutical therapeutics and conditioning agents for oncology and cell/gene therapies with integrated isotope production and manufacturing plans.

A development-stage company with minimal product revenue ($124,157 in 2025) and substantial R&D and operating expenses, reporting a net loss of $14,771,012 in 2025, large intangible assets (~$19.2M) and significant convertible debt on the balance sheet.